Bristol-Myers Squibb Company
BMY
$59.01
-$1.27-2.11%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -94.05% | -27.92% | 114.10% | -775.99% | -8.61% |
| Total Depreciation and Amortization | -29.75% | 0.30% | 6.23% | 0.86% | -0.93% |
| Total Amortization of Deferred Charges | -- | -- | -200.00% | -- | -- |
| Total Other Non-Cash Items | 2,929.27% | -90.26% | -96.51% | 1,580.22% | -1,456.67% |
| Change in Net Operating Assets | -25.25% | 171.99% | -1,297.47% | -76.84% | 193.81% |
| Cash from Operations | -20.60% | 140.37% | -17.93% | -33.35% | -10.50% |
| Capital Expenditure | -16.67% | -23.66% | 7.75% | 13.94% | 3.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 86.49% | 74.65% | 93.15% | -3,351.46% | -78.22% |
| Divestitures | 30.59% | -5.56% | 12.03% | 0.00% | -2.43% |
| Other Investing Activities | -152.53% | 330.43% | -90.38% | 170.71% | -6,245.45% |
| Cash from Investing | 10.50% | 83.40% | 93.28% | -1,357.50% | -228.29% |
| Total Debt Issued | -526.32% | -70.86% | -97.96% | 277.85% | 42,320.00% |
| Total Debt Repaid | 100.00% | 12.12% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 1,150.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.16% | 0.08% | -0.41% | -4.48% | 2.60% |
| Other Financing Activities | -218.75% | 366.67% | 93.81% | -- | -- |
| Cash from Financing | 57.37% | 4.25% | -127.47% | 1,414.37% | 118.74% |
| Foreign Exchange rate Adjustments | -290.91% | 450.00% | 51.11% | -157.69% | 305.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 53.66% | 152.57% | -39.04% | -155.30% | 561.03% |
